SCHEMBL61876

SCHEMBL61876

O=C(O)c1cnc2ccc(O)cc2c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.64
PSMD14 O00487 1/20 0.44
DYRK1A Q13627 2/20 0.42
DYRK1B Q9Y463 2/20 0.42
MAP4K4 O95819 1/20 0.42
CDK8 P49336 1/20 0.42
CLK2 P49760 1/20 0.42
CDK7 P50613 1/20 0.42
CDK9 P50750 1/20 0.42
CDK5 Q00535 1/20 0.42
ACVR1 Q04771 1/20 0.42
ROCK1 Q13464 1/20 0.42
LRRK2 Q5S007 1/20 0.42
CLK4 Q9HAZ1 1/20 0.42
MEN1 O00255 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
KMT2A Q03164 1/20 0.42
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2749769 0.98 MGAM (0.62) MGAMPSMD14DYRK1ADYRK1BMAP4K4
SCHEMBL10465639 0.87 MGAM (0.70) MGAMPSMD14MEN1NPC1RAB9A
SCHEMBL529524 0.87 MGAM (0.57) MGAMPSMD14DYRK1ADYRK1BMAP4K4
SCHEMBL21819406 0.86 MGAM (0.54) MGAMDYRK1ADYRK1BMAP4K4CDK8
SCHEMBL1353291 0.86 MGAM (0.64) MGAMPSMD14MEN1NPC1RAB9A
SCHEMBL12504970 0.83 MGAM (0.56) MGAMPSMD14DYRK1ADYRK1BMAP4K4
SCHEMBL13386768 0.81 MGAM (0.62) MGAMPSMD14P4HA1P4HTMMIF
SCHEMBL2306751 0.81 MGAM (0.62) MGAMPSMD14DRD1P4HA1P4HTM
SCHEMBL12928124 0.81 MGAM (0.62) MGAMPSMD14MEN1NPC1RAB9A
SCHEMBL9508 0.81 MGAM (0.62) MGAMPSMD14P4HA1P4HTM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250275954-A1 USE OF KYNURENIC ACID RESISTING HYPERURICEMIA AND STRUCTURAL ANALOG THEREOF IN PREPARATION OF XOD INHIBITOR UNIV JIMEI (CN) 2025-09-04 US claimed
WO-2025107568-A1 USE OF KYNURENIC ACID IN RESISTING HYPERURICEMIA AND STRUCTURAL ANALOG THEREOF IN PREPARING XOD INHIBITOR 集美大学 2025-05-30 WO claimed
CN-117883445-A Application of hyperuricemia resistance of canine uric acid and structural analogue thereof in preparation of XOD inhibitor 集美大学 2024-04-16 CN claimed
US-20250275954-A1 USE OF KYNURENIC ACID RESISTING HYPERURICEMIA AND STRUCTURAL ANALOG THEREOF IN PREPARATION OF XOD INHIBITOR UNIV JIMEI (CN) 2025-09-04 US disclosed
WO-2025107568-A1 USE OF KYNURENIC ACID IN RESISTING HYPERURICEMIA AND STRUCTURAL ANALOG THEREOF IN PREPARING XOD INHIBITOR 集美大学 2025-05-30 WO disclosed
CN-117883445-A Application of hyperuricemia resistance of canine uric acid and structural analogue thereof in preparation of XOD inhibitor 集美大学 2024-04-16 CN disclosed
EP-2231666-B1 Carboxamide, sulfonamide and amine compounds for metabolic disorders RIGEL PHARMACEUTICALS INC (US) 2015-07-29 EP disclosed
US-8895578-B2 Carboxamide, sulfonamide and amine compounds and methods for using the same RIGEL PHARMACEUTICALS, INC. (US) 2014-11-25 US disclosed
US-8895578-B2 Carboxamide, sulfonamide and amine compounds and methods for using the same RIGEL PHARMACEUTICALS, INC. (US) 2014-11-25 US disclosed
US-8895578-B2 Carboxamide, sulfonamide and amine compounds and methods for using the same RIGEL PHARMACEUTICALS, INC. (US) 2014-11-25 US disclosed
US-20140045882-A1 Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same RIGEL PHARMACEUTICALS, INC. (US) 2014-02-13 US disclosed
WO-2009076631-A1 CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS FOR METABOLIC DISORDERS RIGEL PHARMACEUTICALS, INC. (US) 2009-06-18 WO disclosed
WO-2009076631-A1 CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS FOR METABOLIC DISORDERS RIGEL PHARMACEUTICALS, INC. (US) 2009-06-18 WO disclosed
CN-101365682-A Bicyclic compounds with kinase inhibitory activity MILLENNIUM PHARM INC (US) 2009-02-11 CN disclosed
EP-1957460-A1 BICYCLIC COMPOUNDS WITH KINASE INHIBITORY ACTIVITY MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-08-20 EP disclosed
US-20070149533-A1 Bicyclic compounds with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-06-28 US disclosed
US-20070149533-A1 Bicyclic compounds with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-06-28 US disclosed
US-20070149533-A1 Bicyclic compounds with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-06-28 US disclosed
WO-2007067444-A1 BICYCLIC COMPOUNDS WITH KINASE INHIBITORY ACTIVITY MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-06-14 WO disclosed
CN-1933839-A Compounds and methods of use AMGEN INC (US) 2007-03-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250275954-A1 USE OF KYNURENIC ACID RESISTING HYPERURICEMIA AND STRUCTURAL ANALOG THEREOF IN PREPARATION OF XOD INHIBITOR XDH, DAO, KMO MGAM 1382/4885PSMD14 2758/4885DYRK1A 743/4885
US-20140045882-A1 Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same AK2, PRKAA1, PRKAA2 MGAM 2663/4885PSMD14 3809/4885DYRK1A 610/4885
US-20070149533-A1 Bicyclic compounds with kinase inhibitory activity MAP3K20, MAP3K1, MAP3K5 MGAM 3868/4885PSMD14 3682/4885DYRK1A 544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.